Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival

BACKGROUND: The development of targeted therapies has undoubtedly broadened therapeutic options for patients with colorectal cancer (CRC). The use of bevacizumab to reduce angiogenesis has been associated with improved clinical outcomes. However, an urgent need for prognostic/predictive biomarkers f...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Cancer
Главные авторы: Paiva, Tadeu Ferreira, de Jesus, Victor Hugo Fonseca, Marques, Raul Amorim, da Costa, Alexandre André Balieiro Anastácio, de Macedo, Mariana Petaccia, Peresi, Patricia Maria, Damascena, Aline, Rossi, Benedito Mauro, Begnami, Maria Dirlei, de Lima, Vladmir Cláudio Cordeiro
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2015
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4579833/
https://ncbi.nlm.nih.gov/pubmed/26394830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1648-4
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы